Insulin is required for patients with either form of diabetes mellitus to maintain a healthy blood glucose level. Patients can now self-administer the required amount of insulin thanks to technological advancements in the medical industry. This eliminates the need for periodic visits to medical specialists. Meanwhile, the rising prevalence of diabetes has propelled the demand for minimally invasive devices that inject insulin intravenously into the body. As a result, the market for insulin delivery devices is growing.
Obesity, sedentary lifestyles, and ageing are just a few of the global causes of diabetes. Obesity is the most common cause that leads to the development of diabetes in people. According to the World Health Organization, in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese. 39 million children under the age of 5 were overweight or obese in 2020. Obesity and overweight are two of the most common risk factors for diabetes. The global insulin delivery device market is expected to grow as the prevalence of diabetes rises around the world.
On the negative side, enforcement of strict regulations for approval of such products along with the increasing cost of insulin analogs in diabetes care management may hamper the growth of the market in the forecast period.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Product Type, Distribution Channel, and Region |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Becton, Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG, Medtronic plc, Animas Corporation, Tandem Diabetes Care, Inc., Sanofi, Biocon Ltd., Eli Lilly and Company, Insulet Corporation. |
Covid-19 Impact on Insulin Delivery Devices Market
In addition, the current Insulin Delivery Devices Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Insulin Delivery Devices Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Insulin Delivery Devices Market Segment Overview
According to Product Type, the Insulin Pens accounts for the largest share in the global Insulin Delivery Devices market. It is expected to continue its dominant demand in forthcoming years as well, thanks to its increased safety, efficacy, and adherence to insulin therapy. The device's prominence is due to its user-friendly feature. The device's popularity is driving up its adoption rate. Furthermore, manufacturers are tracking adoption rates and, as a result, are focusing on ongoing device innovation.
Insulin Delivery Devices Market, By Product Type
· Insulin Syringes
· Insulin Pens
· Insulin Pumps
Insulin Delivery Devices Market, By Distribution Channel
· Hospital Pharmacy
· Retail Pharmacy
· Online Sales
· Diabetes Clinics and Centers
Insulin Delivery Devices Market Regional Overview
Geographically, North America is anticipated to dominate the overall market, throughout the forecast period. The high prevalence of diabetes in the United States, particularly type-1 diabetes, is expected to have an impact on the growth of the insulin delivery devices market in North America.
Insulin Delivery Devices Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Insulin Delivery Devices Market, Key Players
· Becton, Dickinson and Company
· Novo Nordisk A/S
· Ypsomed Holding AG
· Medtronic plc
· Animas Corporation
· Tandem Diabetes Care, Inc.
· Sanofi
· Biocon Ltd.
· Eli Lilly and Company
· Insulet Corporation
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the Insulin Delivery Devices market?
Q2. Which Segments are covered in the Insulin Delivery Devices Market report?
Q3. Which segment is projected to hold the largest share in the Insulin Delivery Devices Market?
Q4. Which region holds the largest share in the Insulin Delivery Devices market?
Q5. Which are the prominent players in the Insulin Delivery Devices Market?
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Insulin Delivery Devices Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product Type
- 5.2.1. Insulin Syringes
- 5.2.2. Insulin Pens
- 5.2.3. Insulin Pumps
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacy
- 5.3.2. Retail Pharmacy
- 5.3.3. Online Sales
- 5.3.4. Diabetes Clinics and Centers
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Insulin Delivery Devices Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product Type
- 6.2.1. Insulin Syringes
- 6.2.2. Insulin Pens
- 6.2.3. Insulin Pumps
- 6.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.3.1. Hospital Pharmacy
- 6.3.2. Retail Pharmacy
- 6.3.3. Online Sales
- 6.3.4. Diabetes Clinics and Centers
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Insulin Delivery Devices Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product Type
- 7.2.1. Insulin Syringes
- 7.2.2. Insulin Pens
- 7.2.3. Insulin Pumps
- 7.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.3.1. Hospital Pharmacy
- 7.3.2. Retail Pharmacy
- 7.3.3. Online Sales
- 7.3.4. Diabetes Clinics and Centers
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Insulin Delivery Devices Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product Type
- 8.2.1. Insulin Syringes
- 8.2.2. Insulin Pens
- 8.2.3. Insulin Pumps
- 8.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.3.1. Hospital Pharmacy
- 8.3.2. Retail Pharmacy
- 8.3.3. Online Sales
- 8.3.4. Diabetes Clinics and Centers
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Insulin Delivery Devices Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product Type
- 9.2.1. Insulin Syringes
- 9.2.2. Insulin Pens
- 9.2.3. Insulin Pumps
- 9.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail Pharmacy
- 9.3.3. Online Sales
- 9.3.4. Diabetes Clinics and Centers
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Becton, Dickinson and Company
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Novo Nordisk A/S
- 10.6. Ypsomed Holding AG
- 10.7. Medtronic plc
- 10.8. Animas Corporation
- 10.9. Tandem Diabetes Care, Inc.
- 10.10. Sanofi
- 10.11. Biocon Ltd.
- 10.12. Eli Lilly and Company
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
